Telomir Pharmaceuticals Inc. has announced new in vitro research results showing that its investigational compound, Telomir-1, effectively kills aggressive human leukemia (HL60) cells. These findings expand the oncology profile of Telomir-1 to include blood cancers, adding to previous evidence of activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The study demonstrated that Telomir-1 reduces leukemia cell viability in a clear, dose-dependent manner and uniquely lowers intracellular iron levels, which leukemia cells rely on for growth and survival. The compound also inhibits key histone-demethylase enzymes and reduces abnormal DNA methylation of tumor-suppressor genes, supporting further oncology research by the company. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.